IP Library › Granted Patent US 12,338,285
Granted Patent B2
US 12,338,285 · App. 17/804,934 · Granted Jun 24, 2025

Anti-FcRn antibodies

Inventors: Helene Margaret Finney (Slough, GB); Alastair David Griffiths Lawson (Slough, GB); Stevan Graham Shaw (Slough, GB); Bryan John Smith (Slough, GB); Kerry Louise Tyson (Slough, GB); Lara Kevorkian (Slough, GB); Christoph Meier (Slough, GB); Kaushik Sarkar (Slough, GB); Paul Alan Atherfold (Slough, GB)
Assignee: UCB BIOPHARMA SRL
C07K16/283A61K39/3955A61K47/60A61K47/643G01N33/5047G01N33/564G01N33/6854G01N33/6857G01N33/6893A61K2039/505C07K2317/21C07K2317/24C07K2317/33C07K2317/55C07K2317/565C07K2317/76C07K2317/92G01N2333/70535G01N2500/02G01N2500/10G01N2800/104G01N2800/24G01N2800/28
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,338,285
App. No.
17/804,934
Granted
Jun 24, 2025
Kind
B2
Abstract

The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.

Claims (60)

1. An isolated DNA molecule or a pair of isolated DNA molecules encoding the heavy and light chains of an anti-FcRn antibody or FcRn-binding fragment thereof, wherein

the heavy chain comprises three CDRs, wherein CDR H1 has the sequence given in SEQ ID NO: 1, CDR H2 has the sequence given in SEQ ID NO: 2, and CDR H3 has the sequence given in SEQ ID NO: 3, and

the light chain comprises three CDRs, wherein CDR L1 has the sequence given in SEQ ID NO: 4, CDR L2 has the sequence given in SEQ ID NO: 5 and CDR L3 has the sequence given in SEQ ID NO: 6.

2. The isolated DNA molecule or pair of isolated DNA molecules according to claim 1 , wherein the antibody is humanized.

3. The isolated DNA molecule or pair of isolated DNA molecules according to claim 1 , wherein the heavy chain comprises the sequence given in SEQ ID NO: 29 and the light chain comprises the sequence given in SEQ ID NO: 15.

4. The isolated DNA molecule or pair of isolated DNA molecules according to claim 1 , wherein the heavy chain comprises a sequence having at least 90% identity to the sequence given in SEQ ID NO: 29 and wherein the light chain comprises a sequence having at least 90% identity to the sequence given in SEQ ID NO: 15.

5. The isolated DNA molecule or pair of isolated DNA molecules according to claim 1 , wherein the FcRn-binding fragment is a scFv, Fv, Fab or Fab′ fragment.

6. The isolated DNA molecule or pair of isolated DNA molecules according to claim 1 , wherein the FcRn-binding fragment is a Fab′ fragment having a heavy chain comprising the sequence given in SEQ ID NO: 36 and a light chain comprising the sequence given in SEQ ID NO: 22.

7. The isolated DNA molecule or pair of isolated DNA molecules according to claim 1 , wherein the anti-FcRn antibody is a full length antibody.

8. The isolated DNA molecule or pair of isolated DNA molecules according to claim 7 , wherein the full length antibody is selected from the group consisting of an IgG1, IgG4 and IgG4P.

9. The isolated DNA molecule or pair of isolated DNA molecules according to claim 8 , wherein the antibody has a heavy chain comprising the sequence given in SEQ ID NO: 72, SEQ ID NO: 87 or SEQ ID NO: 43 and a light chain comprising the sequence given in SEQ ID NO: 22.

10. The isolated DNA molecule or pair of isolated DNA molecules according to claim 1 , wherein the antibody or binding fragment thereof is a Fab-dsFv having a heavy chain comprising the sequence given in SEQ ID NO: 50 and a light chain comprising the sequence given in SEQ ID NO: 46 or SEQ ID NO: 78.

11. The isolated DNA molecule or pair of isolated DNA molecules according to claim 1 , wherein the anti-FcRn antibody or FcRn-binding fragment thereof binds human FcRn.

12. The isolated DNA molecule or pair of isolated DNA molecules according to claim 11 , wherein the anti-FcRn antibody or FcRn-binding fragment thereof blocks binding of human IgG to human FcRn.

13. The isolated DNA molecule or pair of isolated DNA molecules according to claim 1 , wherein the anti-FcRn antibody or FcRn-binding fragment thereof does not bind β2 microglobulin.

14. A cloning or expression vector or a pair of cloning or expression vectors encoding the heavy and light chains of an anti-FcRn antibody or FcRn-binding fragment thereof, wherein

the heavy chain comprises three CDRs, wherein CDR H1 has the sequence given in SEQ ID NO: 1, CDR H2 has the sequence given in SEQ ID NO: 2, and CDR H3 has the sequence given in SEQ ID NO: 3, and

the light chain comprises three CDRs, wherein CDR L1 has the sequence given in SEQ ID NO: 4, CDR L2 has the sequence given in SEQ ID NO: 5 and CDR L3 has the sequence given in SEQ ID NO: 6.

15. The cloning or expression vector or pair of cloning or expression vectors according to claim 14 , wherein the antibody is humanized.

16. The cloning or expression vector or pair of cloning or expression vectors according to claim 14 , wherein the heavy chain comprises the sequence given in SEQ ID NO: 29 and the light chain comprises the sequence given in SEQ ID NO: 15.

17. The cloning or expression vector or pair of cloning or expression vectors according to claim 14 , wherein the heavy chain comprises a sequence having at least 90% identity to the sequence given in SEQ ID NO: 29 and wherein the light chain comprises a sequence having at least 90% identity to the sequence given in SEQ ID NO: 15.

18. The cloning or expression vector or pair of cloning or expression vectors according to claim 14 , wherein the FcRn-binding fragment is a scFv, Fv, Fab or Fab′ fragment.

19. The cloning or expression vector or pair of cloning or expression vectors according to claim 18 , wherein the FcRn-binding fragment is a Fab′ fragment having a heavy chain comprising the sequence given in SEQ ID NO: 36 and a light chain comprising the sequence given in SEQ ID NO: 22.

20. The cloning or expression vector or pair of cloning or expression vectors according to claim 14 , wherein the anti-FcRn antibody is a full length antibody.

21. The cloning or expression vector or pair of cloning or expression vectors according to claim 20 , wherein the full length antibody is selected from the group consisting of an IgG1, IgG4 and IgG4P.

22. The cloning or expression vector or pair of cloning or expression vectors according to claim 21 , wherein the antibody has a heavy chain comprising the sequence given in SEQ ID NO: 72, SEQ ID NO: 87 or SEQ ID NO: 43 and a light chain comprising the sequence given in SEQ ID NO: 22.

23. The cloning or expression vector or pair of cloning or expression vectors according to claim 14 , which comprises (i) the sequence given in SEQ ID NO: 37 and the sequence given in SEQ ID NO: 23 or (ii) the sequence given in SEQ ID NO: 80 and the sequence given in SEQ ID NO: 79, or (iii) the sequence given in SEQ ID NO: 93 and the sequence given in SEQ ID NO: 91.

24. The cloning or expression vector or pair of cloning or expression vectors according to claim 14 , wherein the anti-FcRn antibody or FcRn-binding fragment thereof binds human FcRn.

25. The cloning or expression vector or pair of cloning or expression vectors according to claim 24 , wherein the anti-FcRn antibody or FcRn-binding fragment thereof blocks binding of human IgG to human FcRn.

26. The cloning or expression vector or pair of cloning or expression vectors according to claim 14 , wherein the anti-FcRn antibody or FcRn-binding fragment thereof does not bind β2 microglobulin.

27. A host cell comprising a cloning or expression vector or a pair of cloning or expression vectors encoding the heavy and light chains of an anti-FcRn antibody or FcRn-binding fragment thereof, wherein

the heavy chain comprises three CDRs, wherein CDR H1 has the sequence given in SEQ ID NO: 1, CDR H2 has the sequence given in SEQ ID NO: 2, and CDR H3 has the sequence given in SEQ ID NO: 3, and

the light chain comprises three CDRs, wherein CDR L1 has the sequence given in SEQ ID NO: 4, CDR L2 has the sequence given in SEQ ID NO: 5 and CDR L3 has the sequence given in SEQ ID NO: 6.

28. The host cell according to claim 27 , wherein the antibody is humanized.

29. The host cell according to claim 27 , wherein the heavy chain comprises the sequence given in SEQ ID NO: 29 and the light chain comprises the sequence given in SEQ ID NO: 15.

30. The host cell according to claim 27 , wherein the heavy chain comprises a sequence having at least 90% identity to the sequence given in SEQ ID NO: 29 and wherein the light chain comprises a sequence having at least 90% identity to the sequence given in SEQ ID NO: 15.

31. The host cell according to claim 27 , wherein the FcRn-binding fragment is a scFv, Fv, Fab or Fab′ fragment.

32. The host cell according to claim 31 , wherein the FcRn-binding fragment is a Fab′ fragment having a heavy chain comprising the sequence given in SEQ ID NO: 36 and a light chain comprising the sequence given in SEQ ID NO: 22.

33. The host cell according to claim 31 , wherein the FcRn-binding fragment is a Fab-dsFv fragment having a heavy chain comprising the sequence given in SEQ ID NO: 50 and a light chain comprising the sequence given in SEQ ID NO: 46 or 78.

34. The host cell according to claim 31 , wherein the anti-FcRn antibody is a full length antibody.

35. The host cell according to claim 34 , wherein the full length antibody is selected from the group consisting of an IgG1, IgG4 and IgG4P.

36. The host cell according to claim 35 , wherein the anti-FcRn antibody has a heavy chain comprising the sequence given in SEQ ID NO: 72, SEQ ID NO: 87 or SEQ ID NO: 43 and a light chain comprising the sequence given in SEQ ID NO: 22.

37. The host cell according to claim 27 , wherein the anti-FcRn antibody or FcRn-binding fragment thereof binds human FcRn.

38. The host cell according to claim 37 , wherein the anti-FcRn antibody or FcRn-binding fragment thereof blocks binding of human IgG to human FcRn.

39. The host cell according to claim 27 , wherein the anti-FcRn antibody or FcRn-binding fragment thereof does not bind β2 microglobulin.

40. A process for the production of an anti-FcRn antibody or FcRn-binding fragment thereof, the process comprising culturing a host cell that comprises a cloning or expression vector or a pair of cloning or expression vectors encoding the heavy and light chains of an anti-FcRn antibody or FcRn-binding fragment thereof and isolating said antibody or fragment, wherein

the heavy chain comprises three CDRs, wherein CDR H1 has the sequence given in SEQ ID NO: 1, CDR H2 has the sequence given in SEQ ID NO: 2, and CDR H3 has the sequence given in SEQ ID NO: 3, and

the light chain comprises three CDRs, wherein CDR L1 has the sequence given in SEQ ID NO: 4, CDR L2 has the sequence given in SEQ ID NO: 5 and CDR L3 has the sequence given in SEQ ID NO: 6.

41. The process of claim 40 , wherein the antibody is humanized.

42. The process of claim 40 , wherein the heavy chain comprises the sequence given in SEQ ID NO: 29 and the light chain comprises the sequence given in SEQ ID NO: 15.

43. The process of claim 40 , wherein the heavy chain comprises a sequence having at least 90% identity to the sequence given in SEQ ID NO: 29 and wherein the light chain comprises a sequence having at least 90% identity to the sequence given in SEQ ID NO: 15.

44. The process of claim 40 , wherein the FcRn-binding fragment is a scFv, Fv, Fab or Fab′ fragment.

45. The process of claim 44 , wherein the FcRn-binding fragment is a Fab′ fragment having a heavy chain comprising the sequence given in SEQ ID NO: 36 and a light chain comprising the sequence given in SEQ ID NO: 22.

46. The process of claim 44 , wherein the FcRn-binding fragment is a Fab-dsFv fragment having a heavy chain comprising the sequence given in SEQ ID NO: 50 and a light chain comprising the sequence given in SEQ ID NO: 46 or 78.

47. The process of claim 40 , wherein the anti-FcRn antibody is a full length antibody.

48. The process of claim 47 , wherein the full length antibody is selected from the group consisting of an IgG1, IgG4 and IgG4P.

49. The process of claim 48 , wherein the anti-FcRn antibody has a heavy chain comprising the sequence given in SEQ ID NO: 72, SEQ ID NO: 87, or SEQ ID NO: 43 and a light chain comprising the sequence given in SEQ ID NO: 22.

50. The process according to claim 40 , wherein the anti-FcRn antibody or FcRn-binding fragment thereof binds human FcRn.

51. The process according to claim 50 , wherein the anti-FcRn antibody or FcRn-binding fragment thereof blocks binding of human IgG to human FcRn.

52. The process according to claim 40 , wherein the anti-FcRn antibody or FcRn-binding fragment thereof does not bind β2 microglobulin.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2022
From: FINNEY, HELENE MARGARET; LAWSON, ALASTAIR DAVID GRIFFITHS; SHAW, STEVAN GRAHAM; SMITH, BRYAN JOHN; TYSON, KERRY LOUISE; KEVORKIAN, LARA; MEIER, CHRISTOPH; SARKAR, KAUSHIK; ATHERFOLD, PAUL ALAN
To: UCB BIOPHARMA SPRL
Reel/Frame 060086/0444 →
CHANGE OF NAME Recorded Jun 2, 2022
From: UCB BIOPHARMA SPRL
To: UCB BIOPHARMA SRL
Reel/Frame 060256/0940 →
Priority Claims (1)
GB 1208370 · May 14, 2012 · national
Continuity (3)
Division 16271086 · Feb 8, 2019
Division 14400812
Related Publication 20230074381A1 · Mar 9, 2023
References Cited (204)
US 4741900A · Alvarez · 1988 [cited by applicant]
US 5219996A · Bodmer · 1993 [cited by applicant]
US 5585089A · Queen · 1996 [cited by applicant]
US 5667425A · Pineau · 1997 [cited by applicant]
US 7662928B2 · Balthasar · 2010 [cited by applicant]
US 8017739B2 · Eichner · 2011 [cited by applicant]
US 8163881B2 · Ober · 2012 [cited by applicant]
US 8834871B2 · Ober · 2014 [cited by applicant]
US 10233243B2 · Finney · 2019 [cited by applicant]
US 10273302B2 · Atherfold · 2019 [cited by applicant]
US 20020138863A1 · Roopenian · 2002 [cited by applicant]
US 20070092507A1 · Balthasar · 2007 [cited by applicant]
US 20080107601A1 · Lauwereys · 2008 [cited by applicant]
US 20100266530A1 · Roopenian · 2010 [cited by applicant]
US 20140248287A1 · Tenhoor · 2014 [cited by applicant]
US 20150118240A1 · Finney · 2015 [cited by applicant]
US 20160264668A1 · Atherfold · 2016 [cited by applicant]
EP 0392745 · 1990 [cited by applicant]
EP 0948544 · 1999 [cited by applicant]
EP 1090037 · 2001 [cited by applicant]
GB 1320066 · 1973 [cited by applicant]
GB 12083705 · 2013 [cited by applicant]
GB 13200662 · 2015 [cited by applicant]
KR 20130071961A · 2013 [cited by applicant]
WO 1986001533 · 1986 [cited by applicant]
WO 1989000195 · 1989 [cited by applicant]
WO 1989001476 · 1989 [cited by applicant]
WO 1991009967 · 1991 [cited by applicant]
WO 1992002551 · 1992 [cited by applicant]
WO 1992022583 · 1992 [cited by applicant]
WO 1993006231 · 1993 [cited by applicant]
WO 9820734 · 1998 [cited by applicant]
WO 1998025971 · 1998 [cited by applicant]
WO 02060919 · 2002 [cited by applicant]
WO 2003031581 · 2003 [cited by applicant]
WO 2003048208 · 2003 [cited by applicant]
WO 2004051268 · 2004 [cited by applicant]
WO 2004106377 · 2004 [cited by applicant]
WO 2005003169 · 2005 [cited by applicant]
WO 2005003170 · 2005 [cited by applicant]
WO 2005003171 · 2005 [cited by applicant]
WO 2005013912 · 2005 [cited by applicant]
WO 2005113605 · 2005 [cited by applicant]
WO 2005117984 · 2005 [cited by applicant]
WO 2006106323 · 2006 [cited by applicant]
WO 2006118772 · 2006 [cited by applicant]
WO 2007024715 · 2007 [cited by applicant]
WO 2007087289 · 2007 [cited by applicant]
WO 2007098420A2 · 2007 [cited by applicant]
WO 2008038024 · 2008 [cited by applicant]
WO 2008043822A2 · 2008 [cited by applicant]
WO 2009020867A2 · 2009 [cited by applicant]
WO 2009040562 · 2009 [cited by applicant]
WO 2009080764 · 2009 [cited by applicant]
WO 2009131702 · 2009 [cited by applicant]
WO 2010014909A1 · 2010 [cited by applicant]
WO 2010035012 · 2010 [cited by applicant]
WO 2011030107 · 2011 [cited by applicant]
WO 2011061492 · 2011 [cited by applicant]
WO 2011086091 · 2011 [cited by applicant]
WO 2012167039A1 · 2012 [cited by applicant]
WO 2013068571 · 2013 [cited by applicant]
WO 2014019727 · 2014 [cited by applicant]
WO 2014204280A1 · 2014 [cited by applicant]
WO 2015071330 · 2015 [cited by applicant]
Raghavan, M et al., “Investigation of the Interaction between the Class I MHC-Related Fc Receptor and its Immunoglobulin G Ligand,” (1994), Immunity; vol. 1, pp. 303-315. [cited by applicant]
Roopenian, DC et al., “The MHC Class I_Like IgG Receptor Controls Perinatal IgG Transport, IgG Homeostasis, and Fate of IgG-Fc-Coupled Drugs,” (2003), J Immunol; vol. 170, pp. 3528-3533. [cited by applicant]
Sand, KMK et al., “Unraveling the interaction between FcRn and albumin: opportunities for design of albumin-based therapeutics,” (2014), Front. Immunol; vol. 5, Article 682, pp. 1-21. [cited by applicant]
Schmidt, MM et al., “Crystal Structure of an HSA/FcRn Complex Reveals Recycling by Competitive Mimicry of HSA Ligands at a pH-Dependent Hydrophobic Interface,” (2013); vol. 21, pp. 1966-1978. [cited by applicant]
Pyzik, M et al., “FcRn: The architect behind the immune and non-immune functions of IgG and albumin,” (2015), J Immunol; vol. 194, No. 10, pp. 4595-4603. [cited by applicant]
Zhou, J et al., “High Affinity Nucleocapsid Protein Binding to the Mu Psi RNA Packaging Signal of Rous Sarcoma Virus,” (2005), J Mol Biol; vol. 349, pp. 976-988. [cited by applicant]
West, AP et al., “Crystal Structure and Immoglobulin G Binding Properties of the Human Major Histocompatibility Complex-Related Fc Receptor,” (2000), Biochemistry; vol. 39, pp. 9698-96708. [cited by applicant]
Ward, ES et al., “Targeting FcRn for therapy: from live cell imaging to in vivo studies in mice,” (2014), Immunol Lett; vol. 160, No. 2, pp. 158-162. [cited by applicant]
Warncke, M et al., “Different Adaptations of IgG Effector Function in Human and Nonhuman Primates and Implications for Therapeutic Antibody Treatment,” (2012), J Immunol; vol. 188, pp. 4405-4411. [cited by applicant]
Wark, K. L. et al., “Latest Technologies for the enhancement of antibody affinity,” Advanced Drug Delivery Reviews, Aug. 7, 2006, vol. 58, No. 5-6, Elsevier BV, Amsterdam, NL, pp. 657-670. [cited by applicant]
International Search Report of International Application No. PCT/EP2016/060305 mailed Jun. 14, 2016. [cited by applicant]
Written Opinion of the International Searching Authority for International Application No. PCT/EP2016/060305 mailed Jun. 14, 2016. [cited by applicant]
Lu, D. et al., “Fab-scFv fusion protein: an efficient approach to production of bispecific antibody fragments,” Journal of Immunological Methods, vol. 267, No. 2, Sep. 15, 2002, pp. 213-226. [cited by applicant]
Firan et al., “The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of y-globulin in humans,” 2001, International Immunology, vol. 13, No. 8, pp. 993-1002. [cited by applicant]
Holliger and Hudson, “Engineered antibody fragments and the rise of single domains,” Nature Biotechnology, vol. 23, No. 9, pp. 1126-1136, Sep. 2005. [cited by applicant]
Adair, J.R., et al., “Therapeutic antibodies,” Drug Design Reviews—Online, 2005, vol. 2, No. 3, pp. 209-217. [cited by applicant]
Verma, R., et al., “Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems,” Journal of Immunological Methods, vol. 216, Nos. 1-2, pp. 165-181, 1998. [cited by applicant]
Chothia, C. and Lesk, A.M., “Canonical Structures for the Hypervariable Regions of Immunoglobulins,” J. Mol. Biol., vol. 196, pp. 901-917, 1987. [cited by applicant]
Kohler & Milstein, “Continuous cultures of fused cells secreting antibody of predefined specificity,” Nature, Aug. 7, 1975, pp. 495-497, vol. 256, nature Publishing Group. [cited by applicant]
Kozbor, D., et al., “The production of monoclonal antibodies from human lymphocytes,” Immunology Today, vol. 4, No. 3, pp. 72-79, 1983. [cited by applicant]
Cole, S.P.C., et al., “The EBV-hybridoma technique and its application to human lung cancer,” Monoclonal Antibodies and Cancer Therapy, vol. 27, (UCLA Symposia on Molecular and Cellular Biology, New Series, R.A. Reisfel… [cited by applicant]
Babcook, J. S. et al., “A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities (PCR/antibody-forming cells/VH and VL genes/immunoglobulin/pl… [cited by applicant]
Kashmiri, S.V.S., et al., 'SDR grafting—a new approach to antibody humanization', Methods, vol. 36, pp. 25-34, 2005. [cited by applicant]
Vaughan, et al., 'Human antibodies by design,' Nature Biotechnology, vol. 16, No. 6, pp. 535-539, 1998. [cited by applicant]
Riechmann, et al., ‘Reshaping human antibodies for therapy’, Nature, vol. 332, pp. 323-327, 1988. [cited by applicant]
Altschul, S.F. et al., “Basic local alignment search tool,” J. Mol. Biol., vol. 215, No. 3, pp. 403-410, 1990. [cited by applicant]
Gish, W., and States, D.M., “Identification of protein coding regions by data base similarity search,” Nature Genet., vol. 3, No. 3, pp. 266-272, 1993. [cited by applicant]
Madden, T.L., et al., ‘Applications of Network Blast Server’, Meth. Enzymol., vol. 266, pp. 131-141, 1996. [cited by applicant]
Altschul, S.F. et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,” Nucleic Acids Res., vol. 25, No. 17, pp. 3389-3402, 1997. [cited by applicant]
Zhang, J. & Madden, T.L., “PowerBLAST: a new network Blast application for interactive or automated sequence analysis and annotation”, Genome Res., vol. 7, No. 6, pp. 649-656, 1997. [cited by applicant]
Ober, RJ, et al., “Visualizing the Site and Dynamics of IgG Salvage by the MHC Class I-Related Receptor, FcRn,” 2004, The Journal of Immunology, 172, pp. 2021-2029. [cited by applicant]
Borvak, J. et al., “Functional expression of the MHC class I-related receptor, FcRn, in endothelial cells of mice,” 1998, Int. Immunol., vol. 10, No. 9, pp. 1289-1298. [cited by applicant]
Cauza, K. et al., “Expression of FcRn, the MHC Class I-Related Receptor for IgG, in Human Keratinocytes,” Jan. 2005, J. Invest. Dermatol., vol. 124, No. 1, pp. 132-139. [cited by applicant]
Ober et al., “Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies,” 2001, Int. Immunol. vol. 13, No. 12, pp. 1551-1559. [cited by applicant]
Zhu et al, “Remodeling domain interfaces to enhance heterodimer formation,” Protein Science vol. 6, pp. 781-788 (1997). [cited by applicant]
Brinkmann et al., “A recombinant immunotoxin containing a disulfide-stabilized Fv fragment,” Proc. Natl. Acad. Sci. USA, vol. 90, Issue 16, pp. 7538-7542 , (1993). [cited by applicant]
Luo, D. et al., “Vl-Linker-Vh Orientation-Dependent Expression of Single Chain Fv Containing an Engineered Disulfide-Stabilized Bond in the Framework Region,” J. Biochem., vol. 118, No. 4, pp. 825-831 (1995). [cited by applicant]
Young et al, “Thermal stabilization of a single-chain Fv antibody fragment by introduction of a disulphide bond,” FEBS Letters vol. 377, Issue 2, pp. 135-139 (1995). [cited by applicant]
Glockshuber et al, “A comparison of strategies to stabilize immunoglobulin Fv-fragments,” Biochemistry vol. 29, No. 6, pp. 1362-1367 (1990). [cited by applicant]
Wolff et al., “Monoclonal Antibody Homodimers: Enhanced Antitumor Activity in Nude Mice,” Cancer Research, vol. 53, pp. 2560-2565 (1993). [cited by applicant]
Yang, W.P. et al., “CDR Walking Mutagenesis for the Affinity Maturation of a Potent Human Anti-HIV-1 Antibody into the Picomolar Range,” J. Mol. Biol., vol. 254, No. 3, pp. 392-403, 1995. [cited by applicant]
Marks, J.D., et al., “By-passing Immunization Human: Building High Affinity Human Antibodies by Chain Shuffling,” Bio/Technology, vol. 10, pp. 779-783, 1992. [cited by applicant]
Low, N. M., et al., ‘Mimicking Somatic Hypermutation Affinity Maturation of Antibodies Displayed on Bacteriophage Using a Bacterial Mutator Strain’, J. Mol. Biol., vol. 260, No. 3, pp. 359-368, 1996. [cited by applicant]
Patten, P., et al., “Applications of DNA shuffling to pharmaceuticals and vaccines,” Curr. Opin. Biotechnol., vol. 8, No. 6, pp. 724-733, 1997. [cited by applicant]
Thompson, J., et al., “Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain r… [cited by applicant]
Crameri, A., et al., “DNA shuffling of a family of genes from diverse species accelerates directed evolution,” Nature, Jan. 15, 1998, vol. 391, pp. 288-291. [cited by applicant]
Hellstrom, K.E. et al., ‘Antibodies for drug delivery,’ Controlled Drub Delivery, Robinson, et al., eds, Marcel Dekker, Inc., Ed. 2, Chapter 15, pp. 623-653 (1987). [cited by applicant]
Thorpe, P.E., et al., ‘The preparation and cytotoxic properties of antibody-toxin conjugates’, Immunol. Rev., vol. 62, pp. 119-158, 1982. [cited by applicant]
Dubowchik, G.M., et al., “Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs,” Pharmacology and Therapeutics, vol. 83, No. 2, pp. 67-123, 1999. [cited by applicant]
Rajagopal et al., “A form of anti-Tac(Fv) which is both single-chain and disulfide stabilized: comparison with its single-chain and disulfide-stabilized homologs,” Protein Engineering, vol. 10 No. 12 pp. 1453-1459 (1997… [cited by applicant]
Reiter, et al., “Improved Binding and Antitumor Activity of a Recombinant Anti-erbB2 Immunotoxin by Disulfide Stabilization of the Fv Fragment,” Journal of Biological Chemistry vol. 269 No. 28 pp. 18327-18331 (1994). [cited by applicant]
Chapman, A., ‘PEGylated antibodies and antibody fragments for improved therapy: a review’, Advanced Drug Delivery Reviews, vol. 54, No. 4, pp. 531-545, 2002. [cited by applicant]
Harris, J.M., and Zalipsky, S., eds., “Poly(ethyleneglycol) Chemistry and Biological Applications”, American Chemical Society, Washington DC, 1997. [cited by applicant]
Anderson CL et al., “Perspective—FcRn transports albumin: relevance to immunology and medicine,” (2006), Trends Immunol; vol. 27, No. 7, pp. 343-348. [cited by applicant]
Berger, Melvin, “Subcutaneous IgG in neurologic diseases,” (2014), Immunotherapy vol. 6, No. 1, pp. 71-83. [cited by applicant]
Besada, Emilio, “Low immunoglobulin levels increase the risk of severe hypogammaglobulinemia in granulomatosis with polyangiitis patients receiving rituximab,” (2016), BMC Musculoskelet Disord; vol. 17:6, pp. 1-7. [cited by applicant]
Lightwood, D et al., “The Discovery, Engineering and Characterisation of a Highly Potent Anti-Human IL-13 Fab Fragment Designed for Administration by Inalation,” (2013), J Mol Biol; vol. 425, pp. 577-593. [cited by applicant]
Kim, J et al., “Kinetics of FcRn-mediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplified mechanism-based model,” (2007), Clin. Immunol. vol. 122, pp. 146-155. [cited by applicant]
Krishna, M et al., “Immunogenicity to Biotherapeutics—The Role of Anti-drug Immune Complexes,” (2016) Front Immunol; vol. 7, Article 21, pp. 1-13. [cited by applicant]
Li, N et al., “Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases,” (2005), J Clin Invest; vol. 115, No. 12, pp. 3440-3450. [cited by applicant]
Patel, DA et al., “FcRn blockade by Fc engineering ameliorates arthritis in a murine model,” (2011), J Immunol; vol. 187, No. 2, pp. 1015-1022. [cited by applicant]
Neuber, T et al., “Characterization and screening of IgG binding to the neonatal Fc receptor,” (2014), MAbs, vol. 6, Issue 4, pp. 928-942. [cited by applicant]
Nixon, AE et al., “Fully human monoclonal antibody inhibitors of the neonatal Fc receptor reduce circulating IgG in non-human primates,” (2015), Front Immunol; vol. 6, Article 176, pp. 1-13. [cited by applicant]
Oganesyan, V et al., “Structural Insights into Neonatal Fc Receptor-based Recycling Mechanisms,” (2014), Journal of Biological Chemistry; vol. 289, No. 11, pp. 7812-7824. [cited by applicant]
Ohkubo, A et al., “Removal Characteristics of Immunoglobulin G Subclasses by Conventional Plasma Exchange and Selective Plasma Exchange,” (2015), Ther Apher Dial; vol. 19, No. 4, pp. 361-366. [cited by applicant]
Akilesh S et al., “Neonatal FcR Expression in Bone Marrow-Derived Cells Functions to Protect Serum IgG from Catabolism” (2007), J Immunol; vol. 179, pp. 4580-4588. [cited by applicant]
Andersen JT et al., “Cross-species Binding Analyses of Mouse and Human Neonatal Fc Receptor Show Dramatic Differences in Immunoglobulin G and Albumin Binding,” (2010), J Biol Chem; vol. 285, No. 7, pp. 4826-4836. [cited by applicant]
Mezo, AR et al., “Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn,” (2008), Proc Natl Acad Sci U S A; vol. 105, No. 7, pp. 2337-2342. [cited by applicant]
Aalberse et al., “IgG4 breaking the rules,” (2002), Immunology 105, pp. 9-19. [cited by applicant]
Akilesh S et al., “The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease,” (2004), J Clin Invest; vol. 113, No. 9, pp. 1328-1333. [cited by applicant]
Liu L. et al., “Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade,” J Immunol, Apr. 1, 20075, vol. 178, No. 8, pp. 5390-5398. [cited by applicant]
Casset et al., “A peptide mimetic of an anti-CD4 monoclonal antibody by rational design,” Biochemical and Biophysical Research Communication, vol. 307 (2003), pp. 198-205. [cited by applicant]
Chowdhury, P.S. et al., “Improving Antibody Infinite by Mimicking Somatic Hypermutation in Vitro,” Nature Biotechnology, vol. 17, Nature Publishing Group, New York, NY, Jun. 1, 1999, pp. 568-572. [cited by applicant]
Christianson, Gregory J. et al., “Monoclonal antibodies directed against human FcRn and their applications,” mAbs, vol. 4, No. 2, Mar. 2012, pp. 208-216. [cited by applicant]
Claypool et al., “Bidirectional Transepithelial IgG Transport by a Strongly Polarized Basolateral Membrane Fcy-Receptor,” Apr. 2004, Mol. Biol. Cell, vol. 15, No. 4, pp. 1746-1759. [cited by applicant]
Claypool et al., “Functional Reconstitution of Human FcRn in Madin-Darby Canine Kidney Cells Requires Co-expressed Human Beta2-Microglobulin,” 2002, Journal of Biological Chemistry, vol. 277, No. 31, pp. 28038-28050. [cited by applicant]
Feng Y. et al., “Design, expression and characterization of a soluble single-chain functional human neonatal Fc receptor,” Protein expression and purification, Sep. 2011, vol. 79, No. 1, pp. 66-71. [cited by applicant]
Getman, Kate, E. et al., “Pharmacokinetic effects of 4C9, an anti-FcRn antibody, in rates: implications for the use of FcRn inhibitors for the treatment of humoral autoimmune conditions,” Journal of Pharmaceutical Scien… [cited by applicant]
Janeway et al., Immunology Third Edition, Garland Publishing Inc. 1997, Chapter 3, Structure of the Antibody Molecule and Immunoglobulin Genes, pp. 3:1-3:11 (Year: 1997). [cited by applicant]
Matucci, A et al., “Mechanisms of action of Ig preparations: immunolodulatory and anti-inflammatory effects,” (2014), Front Immunol; vol. 5, Article 690, pp. 1-5. [cited by applicant]
Angal, S., et al. “A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody”, Molecular Immunology, vol. 30, No. 1, pp. 105-108, 1993. [cited by applicant]
Dall'Acqua, WF et al., “Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn),” (2006), J Biol Chem; vol. 281, No. 33, pp. 23514-2324. [cited by applicant]
Datta-Mannan, A et al., “Monoclonal Antibody Clearance Impact of Modulating the Interaction of IgG with the Neonatal Fc Receptor,” (2007), J Biol Chem; vol. 282, No. 3, pp. 1709-1717. [cited by applicant]
Fagerberg, L et al., “Analysis of the Human Tissue-specific Expression by Genome-wide Integration of Transcriptomics and Antibody-based Proteomics,” (2014), Mol Cell Proteomics; 13, pp. 397-406. [cited by applicant]
Gonzalez-Noriega, A et al., “Chloroquine inhibits lysosomal enzyme pinocytosis and enhances lysosomal enzyme secretion by impairing receptor recycling,” (1980), J Cell Biol; vol. 85, pp. 839-852. [cited by applicant]
Humphreys, F et al., “The characteristics of urticaria in 390 patients,” (1998), Br J Dermatol; vol. 138, pp. 635-638. [cited by applicant]
Kiessling, P et al., “The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study,” (2017), Sci Transl Med; col. 9, pp. 1-12. [cited by applicant]
Zhou, J et al., “Conferring the Binding Properties of the Mouse MHC Class I-related Receptor, FcRn, onto the Human Ortholog by Sequential Rounds of Site-directed Mutagenesis,” (2005), J Mol Biol; vol. 345, pp. 1071-1081. [cited by applicant]
Petkova, SB et al., “Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease,” (2006), Int Immunol; vol. 18, No.… [cited by applicant]
Altshuler, E.P. et al., “Generation of Recombinant Antibodies and Means for Increasing Their Affinity,” Biochemistry, Dec. 1, 2010, vol. 75, No. 13, pp. 1584-1605. [cited by applicant]
Paul et al., Fundamental Immunology, 3rd ed. 1993, p. 242. [cited by applicant]
Portolano et al., “Lack of Promiscuity in Autoantigen-Specific H and L Chain Combinations as Revealed by Human H and L Chain Roulette,” Journal of Immunology, 1993, vol. 150, pp. 880-887. [cited by applicant]
Raghavan, M. et al., “Analysis of pH Dependence of the Neonatal Fc Receptor/ Immunoglobulin G Interaction Using Antibody and Receptor Variants,” Biochemistry, vol. 34, No. 45, 1995, pp. 14649-14657. [cited by applicant]
Ravetch, J.V., et al., ‘Structure of the human immunoglobulin mu locus: characterization of embryonic and rearranged J and D genes’, Cell, vol. 27, No. 3, Pt 2, pp. 583-591, 1981. [cited by applicant]
Roopenian and Akilesh, “FcRn: the neonatal Fc receptor comes of age,” Nature Reviews Immunology, Sep. 2007, vol. 7, pp. 715-725. [cited by applicant]
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity”, PNAS 1982. vol. 79 p. 1979-1983 (Year: 1982). [cited by applicant]
Scatchard et al., “The attractions of proteins for small molecules and ions,” Annals New York Academy of Science, vol. 51, pp. 660-672 (1949). [cited by applicant]
Vaccaro C. et al., “Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels,” Nature Biotechnology, Oct. 2005, vol. 23, No. 10, pp. 1283-1288. [cited by applicant]
Liu, Z et al., “Beta 2-microglobulin-deficient Mice Are Resistant to Bullous Pemphigoid,” (1997), J Exp Med; vol. 186, No. 5, pp. 777-783. [cited by applicant]
Martins, JP et al., “A comprehensive review of the neonatal Fc receptor and its application in drug delivery,” (2016), Pharmacol Ther; vol. 161, pp. 22-39. [cited by applicant]
Zubler, R. H. et al., “Mutant EL-4 thymoma cells polyclonally activate murine and human B cells via direct cell interaction,” J. Immunol., vol. 134, pp. 3662-3668 (1985). [cited by applicant]
Schwartz, J et al., “Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Sixth Special Issue,” (2013), J Clin… [cited by applicant]
Sewell, WA et al., “European consensus proposal for immunoglobulin therapies,” (2014), Eur. J. Immunol; vol. 44, pp. 2207-2214. [cited by applicant]
Uno, Y et al., “Polymorphisms of Neonatal Fc Receptor in Cynomolgus and Rhesus Macaques,” (2014), Drug Metab Pharmacokinet; vol. 29, No. 5, pp. 427-430. [cited by applicant]
Waldmann, TA et al., “Familial Hypercatabolic Hypoproteinemia,” (1990), J Clin Invest; vol. 86, pp. 2093-2098. [cited by applicant]
Wang, J et al., “Intravenous immunoglobulin in critically ill adults: When and what is the evidence?” (2015), J Crit Care; vol. 30, pp. 652.e9-652e.16. [cited by applicant]
Wani, MA et al., “Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant beta2-microglobulin gene,” (2006), Proc Natl Acad Sci U S A; vol. 103, No. 13, pp. 5084-2… [cited by applicant]
Harris, R.J., “Processing of C-terminal lysine and arginine residues of proteins isolated from mammalian cell culture,” Journal of Chromatography, vol. 705, No. 1, pp. 129-134, 1995. [cited by applicant]
Written Opinion of the International Searching Authority for International Application No. PCT/EP2013/059802 mailed Jan. 2, 2014. [cited by applicant]
Hieter, P.A., et al., ‘Evolution of human immunoglobulin kappa J region genes’, J. Biol. Chem., vol. 257, No. 3, pp. 1516-1522, 1982. [cited by applicant]
International Search Report, International Application PCT/EP2013/059802, mailed Jan. 2, 2014. [cited by applicant]
Junghans, RP et al., “The ptoection receiption for lgG catabolismis the Beta 2-microglobulin-containing neonatal intestinal transport receptor,” (1996), Proc Natl Acad Sci U S A; vol. 93, pp. 5512-5516. [cited by applicant]
Dall'Acqua, WF et al., “Increasing the Affinity of a Human IgG1 for the Neonatal Fc Receptor: Biological Consequences,” (2002), J Immunol; vol. 169, pp. 5171-5180. [cited by applicant]
Cain K et al., “A CHO Cell Line Engineered to Express XBP1 and ERO1-Lx Has Increased Levels of Transient Protein Expression,” (2013), Biotechnol Prog; vol. 29, No. 3, pp. 697-706. [cited by applicant]
Burmesiter, et al., “Crystal structure of the complex of rat neonatal Dc receptor with Fc,” Nature, vol. 372, Nov. 24, 1994 , pp. 379-383. [cited by applicant]
Alina Sesarman et al., “The neonatal Fc receptor as therapeutic target in IgG-mediated autoimmune diseases,” CMLS Cellular and Molecular Life Sciences, vol. 67, No. 15, Mar. 9, 2010, pp. 2533-2550. [cited by applicant]
International Search Report mailed Feb. 17, 2015 for International Application No. PCT/EP2014/074409. [cited by applicant]
Kabat, et al., ‘Sequences of Proteins of Immunological Interest’, 4th ed., US Department of Health and Human Services, Public Health Service, National Institutes of Health, 1983, pp. xv-xviii. [cited by applicant]
Written Opinion of the International Searching Authority mailed Feb. 17, 2015 for International Application No. PCT/EP2014/074409. [cited by applicant]
Co-pending U.S. Appl. No. 14/400,812, filed Nov. 13, 2014—IFW listing from Patent Center only, Now issued U.S. Pat. No. 10,233,243. [cited by applicant]
Co-pending U.S. Appl. No. 15/036,209, filed May 12, 2016—IFW listing from Patent Center only, Now Issued U.S. Pat. No. 10,273,302. [cited by applicant]
Co-pending U.S. Appl. No. 15/573, 185, filed Nov. 10, 2017—IFW listing from Patent Center only, now Abandoned. [cited by applicant]
Co-pending U.S. Appl. No. 16/271,086, filed Feb. 8, 2019—IFW listing from Patent Center only, now Issued as U.S. Pat. No. 11,384,148. [cited by applicant]
Zanella, A., et al., “Treatment of autoimmune hemolytic anemias”, Haematologica 2014, 99(10):1547-1554. [cited by applicant]
Co-pending U.S. Appl. No. 16/622,658, filed Dec. 13, 2019—IFW listing from Patent Center only. [cited by applicant]
Co-pending U.S. Appl. No. 16/300,522, filed Nov. 9, 2018—IFW listing from Patent Center only, now Issued as U.S. Pat. No. 11,407,835. [cited by applicant]
Co-pending U.S. Appl. No. 16/299,407, filed Mar. 12, 2019—IFW listing from Patent Center only, now Issued U.S. Pat. No. 11,220,547. [cited by applicant]
Co-pending U.S. Appl. No. 17/286,247, filed Apr. 16, 2021—IFW listing from Patent Center only. [cited by applicant]
Co-pending U.S. Appl. No. 16/615,419, filed Nov. 21, 2019—IFW listing from Patent Center only. [cited by applicant]
Office Action, Japanese Patent Application No. JP2020-093532, Jul. 20, 2021. [cited by applicant]
English translation of Office Action, Japanese Patent Application No. JP2020-093532, Jul. 20, 2021. [cited by applicant]
Examination Report issued in Argentine Application No. 20130101652 on Jun. 23, 2023. [cited by applicant]
English translation of Examination Report issued in Argentine Application No. 20130101652 on Jun. 23, 2023. [cited by applicant]
Sockolosky JT, Tiffany MR, Szoka FC. Engineering neonatal Fc receptor-mediated recycling and transcytosis in recombinant proteins by short terminal peptide extensions. Proc Natl Acad Sci U S A. Oct. 2, 2012;109(40):1609… [cited by applicant]
Ramalingam TS, Detmer SA, Martin WL, Bjorkman PJ. IgG transcytosis and recycling by FcRn expressed in MDCK cells reveals ligand-induced redistribution. EMBO J. Feb. 15, 2002;21(4):590-601. doi: 10.1093/emboj/21.4.590. R… [cited by applicant]
Tesar DB, Tiangco NE, Bjorkman PJ. Ligand valency affects transcytosis, recycling and intracellular trafficking mediated by the neonatal Fc receptor. Traffic. Sep. 2006;7(9):1127-42. doi: 10.1111/j.1600-0854.2006.00457.… [cited by applicant]
Ramalingam TS, Detmer SA, Martin WL, Bjorkman PJ, EMBO J. Nov. 1, 2002;21(21):5953. PMID: 11847107; PMCID: PMC125858. [cited by applicant]
Examination report No. 1 for standard patent application, Australian Patent Application No. 2020217370, Apr. 14, 2023. [cited by applicant]
McCarthy et al., Bidirectional transcytosis of IgG by the rat neonatal Fc receptor expressed in a rat kidney cell line; a system to study protein transport across epithelia, Journal of Cell Science, 113:1277-1285 (2000). [cited by applicant]